Researchers from National Cancer Institute have found the benefits of recombinant poxviral vaccine on victims of Ovarian and breast cancer.
During the study, 12 patients with breast cancer were administered the vaccine and the research found that the median time to progression was 2.5 months with a median overall survival of 13.7 months.
Among 14 ovarian cancer patients who received the vaccine, the median time to progression was two months with median overall survival of 15.0 months.
Monthly injections of PANVAC vaccines were given to participants expressing tumor-associated antigens (TAA) for carcinoembryonic antigen (CEA) and mucin-1 along with three T-cell costimulatory molecules. Out of the 26 participants, nearly 21 of them had already received three or more rounds of chemotherapy.
"In the study reported here, some patients who had limited tumor burden and whose immune system was not compromised by multiple rounds of chemotherapy seemed to benefit from the vaccine," researchers said.